{"title":"Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder.","authors":"George I Papakostas","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Treatment-resistant depression (TRD) is not uncommon; 29% to 46% of patients with depression who are treated with antidepressants fail to respond fully. Dr. Papakostas discusses various augmentation strategies, focusing particular on a possible role for the newer atypical antipsychotics. Their complex neuropharmacological actions suggest such efficacy. One chart review and a number of open-label studies have been encouraging, but 2 double-blind, placebo controlled-studies have offered contradictory results. Considering the side-effect profiles of these drugs, a careful risk/benefit assessment is always required. While routinely used for psychotic depression and panic reactions in depressive disorders, their value as augmenters in TRD awaits further study.</p>","PeriodicalId":87179,"journal":{"name":"Essential psychopharmacology","volume":"6 4","pages":"209-20"},"PeriodicalIF":0.0000,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Essential psychopharmacology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Treatment-resistant depression (TRD) is not uncommon; 29% to 46% of patients with depression who are treated with antidepressants fail to respond fully. Dr. Papakostas discusses various augmentation strategies, focusing particular on a possible role for the newer atypical antipsychotics. Their complex neuropharmacological actions suggest such efficacy. One chart review and a number of open-label studies have been encouraging, but 2 double-blind, placebo controlled-studies have offered contradictory results. Considering the side-effect profiles of these drugs, a careful risk/benefit assessment is always required. While routinely used for psychotic depression and panic reactions in depressive disorders, their value as augmenters in TRD awaits further study.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
